Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-cash Items (2016 - 2025)

Cytokinetics (CYTK) has disclosed Non-cash Items for 13 consecutive years, with $305.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items changed N/A to $305.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $305.4 million, a N/A change, with the full-year FY2025 number at $305.4 million, changed N/A from a year prior.
  • Non-cash Items was $305.4 million for Q4 2025 at Cytokinetics, up from $7.3 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $305.4 million in Q4 2025 to a low of $200000.0 in Q3 2022.
  • A 4-year average of $125.4 million and a median of $7.3 million in 2023 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: surged 5195.92% in 2021, then plummeted 97.22% in 2023.
  • Cytokinetics' Non-cash Items stood at $302.1 million in 2021, then fell by 13.31% to $261.9 million in 2022, then tumbled by 97.22% to $7.3 million in 2023, then soared by 4095.45% to $305.4 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Non-cash Items are $305.4 million (Q4 2025), $7.3 million (Q4 2023), and $261.9 million (Q4 2022).